New Two-Drug attack on deadly brain cancer begins human testing
NCT ID NCT04656535
Summary
This early-phase study is testing the safety of a new two-drug combination (domvanalimab and zimberelimab) for adults with glioblastoma that has returned after initial treatment. The trial will enroll 46 patients to see how well the drugs are tolerated and to study their effects on the tumor and immune system. Some participants will receive the drugs before a planned surgery to allow researchers to directly analyze the treatment's impact on the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
Yale University
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.